3-fluoro-4-(1H-1,2,3,4-tetrazol-1-yl)benzoic acid → N-[1-(5-Chloro-pyrimidin-2-yl)-piperidin-4-yl]-N-cyclopropyl-3-fluoro-4-tetrazol-1-yl-benzamide
반응식
[Cl:1][C:2]1[CH:3]=[N:4][C:5]([N:8]2[CH2:13][CH2:12][CH:11]([NH:14][CH:15]3[CH2:17][CH2:16]3)[CH2:10][CH2:9]2)=[N:6][CH:7]=1.[F:18][C:19]1[CH:20]=[C:21]([CH:25]=[CH:26][C:27]=1[N:28]1[CH:32]=[N:31][N:30]=[N:29]1)[C:22](O)=[O:23]>>[Cl:1][C:2]1[CH:3]=[N:4][C:5]([N:8]2[CH2:13][CH2:12][CH:11]([N:14]([CH:15]3[CH2:17][CH2:16]3)[C:22](=[O:23])[C:21]3[CH:25]=[CH:26][C:27]([N:28]4[CH:32]=[N:31][N:30]=[N:29]4)=[C:19]([F:18])[CH:20]=3)[CH2:10][CH2:9]2)=[N:6][CH:7]=1참가 물질
3
실험 절차
The title compound is prepared from [1-(5-chloro-pyrimidin-2-yl)-piperidin-4-yl]-cyclopropyl-amine and 3-fluoro-4-tetrazol-1-yl-benzoic acid following a procedure analogous to that described in Example 107. LC (method 19): tR=4.18 min; Mass spectrum (ESI+): m/z=443 [M+H]+.
출처 및 근거
- ORD 기록
- ord-abb06a395f9645e6ba81f3e7d44b684b
- 출처 데이터셋
- uspto-grants-2014_09
- DOI